Nitrogen Attached Directly To The Cyclopentanohydrophenanthrene Ring System By Nonionic Bonding Patents (Class 540/106)
  • Patent number: 10323059
    Abstract: Described herein are neuroactive steroids of the Formula (I): or a pharmaceutically acceptable salt thereof; wherein R1a and R1b are as defined herein. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. The present invention also provides pharmaceutical compositions comprising a compound of the present invention and methods of use and treatment, e.g., such for inducing sedation and/or anesthesia.
    Type: Grant
    Filed: September 7, 2017
    Date of Patent: June 18, 2019
    Assignee: Sage Therapeutics, Inc.
    Inventors: Gabriel Martinez Botella, Boyd L. Harrison, Albert J. Robichaud, Francesco G. Salituro
  • Patent number: 10172871
    Abstract: Provided herein are 19-nor C3,3-disubstituted C21-pyrazolyl steroids of Formula (I): and pharmaceutically acceptable salts thereof; wherein , R1, R2, R3a, R3b, R4a, R4b, R5, R6, and R7 are as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and/or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and/or withdrawal syndromes, and tinnitus.
    Type: Grant
    Filed: October 19, 2016
    Date of Patent: January 8, 2019
    Assignee: Sage Therapeutics, Inc.
    Inventors: Gabriel Martinez Botella, Boyd L. Harrison, Albert Jean Robichaud, Francesco G. Salituro, Richard Thomas Beresis
  • Publication number: 20150099727
    Abstract: This application is directed to the use of aminosteroid compounds for the selective inhibition of the enzyme PTP1B in a mammal for the treatment of diabetes.
    Type: Application
    Filed: April 19, 2013
    Publication date: April 9, 2015
    Applicant: Ohr Pharmaceutical Inc.
    Inventors: Michael McLane, Inez Ruiz-White, W. Lee Maloy, Henry R. Wolfe
  • Publication number: 20140309417
    Abstract: The present invention relates to a process for the preparation of sterol derivatives comprising the reaction of an ?-epoxy compound with an amine in an alcohol comprising 3 to 5 carbon atoms as a solvent.
    Type: Application
    Filed: November 23, 2012
    Publication date: October 16, 2014
    Inventors: Marc Poirot, Michael Paillasse, Philippe De Medina, Sandrine Poirot
  • Patent number: 8841284
    Abstract: There is provided a novel compound having neurite-outgrowing activity that is useful for the prevention or the treatment of a neurodegenerative disease. A compound of Formula (I) [where X is OR or NR1R2, Y is OH, NR3R4, —NHC(?NH)NHR5, or —NHC(?NH)R5, and Z is a hydrogen atom, a linear or branched C1-5 alkyl group, or a 5- or 6-membered ring aryl group optionally having 1 or 2 nitrogen atom(s), sulfur atom(s), or oxygen atom(s)], or a pharmaceutically or veterinary-medically acceptable salt of the compound.
    Type: Grant
    Filed: July 21, 2009
    Date of Patent: September 23, 2014
    Assignee: Lead Chemical Co., Ltd
    Inventors: Hideo Nemoto, Yuji Matsuya
  • Publication number: 20140274984
    Abstract: The present invention relates to acid addition salts of 5?-hydroxy-6?-[2-(1H-imidazol-4-yl)ethylamino]cholestan-3?-ol, to their preparation and to applications thereof.
    Type: Application
    Filed: October 17, 2012
    Publication date: September 18, 2014
    Applicants: AFFICHEM, INSERM (Institute National de la Sante et de la Recherche Medicale
    Inventors: Marc Poirot, Sandrine Poirot, Philippe de Medina, Michael Paillasse
  • Publication number: 20140249122
    Abstract: The present invention relates to novel aminosteroid derivatives substituted in position 3 andor 6, and to the use thereof in the context of the treatment of type 2 diabetes and of insulin resistance.
    Type: Application
    Filed: October 16, 2012
    Publication date: September 4, 2014
    Applicants: UNIVERSITE NICE SOPHIA ANTIPOLIS, UNIVERSITE D'AIX-MARSEILLE, INSERM (Institut National de la Sante Et de la Recherche Medicate), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFQUE
    Inventors: Roland Marinus Theodorus Govers, Jean-Michel Brunel
  • Patent number: 8664210
    Abstract: New aminooxime derivatives at position 3 of 2- and/or 4-substituted androstanes and androstenes, processes for their preparation, and to pharmaceutical compositions containing them for the treatment of cardiovascular disorders, such as heart failure and hypertension. In particular compounds having the general formula (I) are described, where the radicals have the meanings described in detail in the application.
    Type: Grant
    Filed: September 18, 2008
    Date of Patent: March 4, 2014
    Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
    Inventors: Alberto Cerri, Giuseppe Bianchi, Giorgio Fedrizzi, Patrizia Ferrari, Mauro Gobbini, Marco Torri, Giuseppe Marazzi, Walter Cabri
  • Patent number: 8653054
    Abstract: Novel chemical agents are described herein. More specifically, 2-(N-substituted piperazinyl) pregnane and 2-(N-substituted piperazinyl) androstane derivatives exhibiting cytotoxicity on a variety of cancer cell lines are disclosed herein.
    Type: Grant
    Filed: November 25, 2009
    Date of Patent: February 18, 2014
    Assignee: Universite Laval
    Inventors: Donald Poirier, Jenny Roy, Rene Maltais
  • Publication number: 20130303500
    Abstract: The invention features compounds, pharmaceutical compositions and methods useful for the treatment of neoplasia. In particular embodiments, the compounds of the invention are useful for the treatment of multidrug resistant neoplasia.
    Type: Application
    Filed: July 29, 2011
    Publication date: November 14, 2013
    Applicant: Medexis S.A.
    Inventors: Konstantinos Alevizopoulos, Theodora Calogeropoulou
  • Publication number: 20130065325
    Abstract: Zwitterion-containing compounds for the modification of hydrophobic molecules to improve their solubility and/or to lower their non-specific binding as provided. The zwitterion-containing compounds may be suitable for modification of detectable labels such as biotin and fluorescein to improve their solubility. The zwitterion-containing compounds may also be useful for the preparation of conjugates of proteins, peptides and other macromolecules or for crosslinking molecules and/or macromolecules.
    Type: Application
    Filed: May 18, 2011
    Publication date: March 14, 2013
    Applicant: SIEMENS HEALTHCARE DIAGNOSTICS INC.
    Inventors: Anand Natrajan, David Sharpe, David Wen, Qingping Jiang
  • Publication number: 20130035304
    Abstract: This invention relates to compounds which selectively bind to the survival protein MCL-1 with high affinity and selectivity, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for modulating MCL-1 activity and for treating hyperproliferative disorders, angiogenesis disorders, cell cycle regulation disorders, autophagy regulation disorders, inflammatory disorders, and/or infectious disorders and/or for enhancing cellular engraftment and/or wound repair, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: January 31, 2011
    Publication date: February 7, 2013
    Inventors: Loren D. Walensky, Michelle L. Stewart, Nicole Cohen
  • Publication number: 20120238488
    Abstract: The invention features compounds, pharmaceutical compositions and methods useful for the treatment of neoplasia. In particular embodiments, the compounds of the invention are useful for the treatment of multidrug resistant neoplasia.
    Type: Application
    Filed: June 22, 2010
    Publication date: September 20, 2012
    Inventors: Konstantinos Alevizopoulos, Theodora Calogeropoulou, Christos Stournaras
  • Publication number: 20120190659
    Abstract: Compounds of Structural Formula I or pharmaceutically acceptable salts thereof, are effective inhibitors of angiogenesis:
    Type: Application
    Filed: April 16, 2010
    Publication date: July 26, 2012
    Applicants: Children's Medical Center Corporation, President and Fellows of Harvard College
    Inventors: Elias James Corey, Barbara Czakó, László Kürti, Akiko Mammoto, Donald E. Ingber
  • Patent number: 8119619
    Abstract: Steroid compounds possessing a hydrogen donor in 3beta position, either in the form of a hydroxy- or a sulfate group, function as efficient blockers of the 3alpha-hydroxy-pregnan-steroid action and thus have utility as therapeutic substances for the prevention and/or treatment of steroid related CNS disorders. Treatment methods based on the administration of these substances are disclosed, and these substances either alone or in combination are also suggested for the manufacture of pharmaceuticals for the treatment of many specific steroid induced CNS disorders.
    Type: Grant
    Filed: January 7, 2011
    Date of Patent: February 21, 2012
    Assignee: Umecrine AB
    Inventors: Torbjörn Bäckström, Per Lundgren, Ming-De Wang, Inga-Maj Johansson
  • Patent number: 7960367
    Abstract: Steroid compounds processing a hydrogen donor in 3beta position, either in the form of a hydroxy- or a sulfate group, function as efficient blockers of the 3alpha-hydroxy-pregnan-steroid action and thus have utility as therapeutic substances for the prevention and/or treatment of steroid related CNS disorders. Treatment methods based on the administration of these substances are disclosed, and these substances either alone or in combination are also suggested for the manufacture of pharmaceuticals for the treatment of many specific steroid induced CNS disorders.
    Type: Grant
    Filed: December 20, 2002
    Date of Patent: June 14, 2011
    Assignee: Umecrine AB
    Inventors: Torbjorn Backstrom, Per Lundgren, Ming-De Wang, Inga-Maj Johansson
  • Patent number: 7910571
    Abstract: The invention relates to the use of compounds to ameliorate or treat an condition such as a cystic fibrosis, neutropenia or other exemplified conditions. Exemplary compounds that can be used include 3?-hydroxy-17?-aminoandrost-5-ene, 3?-hydroxy-16?-fluoro-17?-aminoandrost-5-ene, 3?-hydroxy-16?-fluoro-17?-aminoandrost-5-ene, 3?-hydroxy-16?-fluoro-17?-aminoandrost-5-ene, 1?,3?-dihydroxy-4?-fluoroandrost-5-ene-17-one, 1?,3?,17?-trihydroxy-4?-fluoroandrost-5-ene, 1?,3?-dihydroxy-6?-bromoandrost-5-ene, 1?-fluoro-3?,12?-dihydroxyandrost-5-ene-17-one, 1?-fluoro-3?,4?-dihydroxyandrost-5-ene and 4?-fluoro-3?,6?,17?-trihydroxyandrostane.
    Type: Grant
    Filed: October 13, 2006
    Date of Patent: March 22, 2011
    Assignee: Harbor BioSciences, Inc.
    Inventor: James M. Frincke
  • Patent number: 7888340
    Abstract: Steroid compounds processing a hydrogen donor in 3beta position, either in the form of a hydroxy- or a sulfate group, function as efficient blockers of the 3alpha-hydroxy-pregnan-steroid action and thus have utility as therapeutic substances for the prevention and/or treatment of steroid related CNS disorders. Treatment methods based on the administration of these substances are disclosed, and these substances either alone or in combination are also suggested for the manufacture of pharmaceuticals for the treatment of many specific steroid induced CNS disorders.
    Type: Grant
    Filed: December 20, 2002
    Date of Patent: February 15, 2011
    Assignee: Umecrine AB
    Inventors: Torbjorn Backstrom, Per Lundgren, Ming-De Wang, Inga-Maj Johansson
  • Publication number: 20100249082
    Abstract: The invention features compounds of formula (I): and pharmaceutically acceptable salts and prodrugs thereof, as well methods for modulating the effects of local and systemic hypoxic events using the compounds.
    Type: Application
    Filed: January 31, 2008
    Publication date: September 30, 2010
    Applicant: Bionaut Pharmaceuticals INC.
    Inventors: Hans-Jurgen Hess, Sajjat Hussoin, Oliver Schwarz
  • Publication number: 20100029906
    Abstract: The present invention relates to new synthetic receptors. More particularly, the present invention relates to the use of the synthetic receptors for delivering a protein, peptide, drug, prodrug, lipid, nucleic acid, carbohydrate or small molecule into a target cell via receptor-mediated endocytosis. According to the invention, novel synthetic mimics of cell surface receptors have been designed and methods for use of the same are disclosed.
    Type: Application
    Filed: December 16, 2008
    Publication date: February 4, 2010
    Applicant: THE PENN STATE RESEARCH FOUNDATION
    Inventor: Blake R. Peterson
  • Publication number: 20090298175
    Abstract: The present invention relates to steroidal ligands for use in nuclear receptor-based inducible gene expression systems. The invention further relates to methods of modulating the expression of genes of interest with a system containing one or more nuclear receptor complexes and one or more steroidal ligands. Further aspects include ligand compositions including therapeutic compositions.
    Type: Application
    Filed: March 16, 2009
    Publication date: December 3, 2009
    Inventors: Robert E. Hormann, Silvia Lapenna, Laurence Neil Dinan
  • Patent number: 7557097
    Abstract: Compounds that function as lamprey attractants and methods.
    Type: Grant
    Filed: November 20, 2004
    Date of Patent: July 7, 2009
    Assignee: Regents of the University of Minnesota
    Inventors: Peter W. Sorensen, Thomas R. Hoye, Jared M. Fine, Vadims Dvornikovs, Jizhou Wang, Lance A. Vrieze
  • Patent number: 7018991
    Abstract: The invention is directed to a novel class of steroids which exhibit potent antiprogestational activity.
    Type: Grant
    Filed: July 2, 2003
    Date of Patent: March 28, 2006
    Assignee: Research Triangle Institute
    Inventors: C. Edgar Cook, John A. Kepler, Gary S. Bartley, Rupa S. Shetty
  • Publication number: 20030212051
    Abstract: Many compounds have poor bioavailability or variable bioavailability because of poor absorption of the compound in the small intestine. Conjugation of the compound with bile acid to form a prodrug will increase the bioavailibility of the compound and/or reduce the bioavailability variability of the compound because of the active transport of the prodrug by the intestinal bile acid transporter and because of increased lipophilic nature of the prodrug. A linker group can be used between the bile acid and the compound. One example of a bile acid containing prodrug is acyclovir valylchenodeoxycholate, where valine is the linker group. Another example of this prodrug is atenolol cholic acid amide.
    Type: Application
    Filed: March 21, 2003
    Publication date: November 13, 2003
    Inventors: James E Polli, Andrew Coop, Dean Y Maeda, Kimberly A Lentz
  • Patent number: 6596885
    Abstract: Novel compounds having a formula selected from the group consisting of wherein the substituents are defined as in the specification which are intermediates for the production of vinyl compounds having a remarkable anti-estrogenic and anti-proliferative activity.
    Type: Grant
    Filed: June 26, 2001
    Date of Patent: July 22, 2003
    Assignee: Aventis Pharma S.A.
    Inventors: Andre Claussner, Francois Nique, Jean-Georges Teutsch, Patrick Van de Velde
  • Patent number: 6541464
    Abstract: Compounds of the formula Where the substituents are defined in the application.
    Type: Grant
    Filed: February 14, 2002
    Date of Patent: April 1, 2003
    Assignee: Aventis Pharma S.A.
    Inventors: Yamina Bouali, Francois Nique, Jean-Georges Teutsch, Patrick Van De Velde
  • Patent number: 6472382
    Abstract: A subject of the invention is the compounds of formula (I): in which X is a halogen atom, D represents the remainder of an optionally substituted pentagonal or hexagonal ring and optionally carrying an unsaturation, R1, R2, R3, R4, Y and n are as defined in the description, their preparation process and intermediates, their use as medicaments and the compositions containing them.
    Type: Grant
    Filed: December 8, 2000
    Date of Patent: October 29, 2002
    Assignee: Aventis Pharma S.A.
    Inventors: Yamina Bouali, Francois Nique, Jean-Georges Teutsch, Patrick Van De Velde
  • Patent number: 6399766
    Abstract: A subject of the invention is the compounds of formula (I): in which X is a halogen atom, D represents the remainder of an optionally substituted pentagonal or hexagonal ring and optionally carrying an unsaturation, R1, R2, R3, R4, Y and n are as defined in the description, their preparation process and intermediates, their use as medicaments and the compositions containing them.
    Type: Grant
    Filed: January 10, 2001
    Date of Patent: June 4, 2002
    Assignee: Aventis Pharma S.A.
    Inventors: Yamina Bouali, Francois Nique, Jean-Georges Teutsch, Patrick Van De Velde
  • Patent number: 6369247
    Abstract: The instant invention involves a process for oxidizing compounds containing an allylic group, i.e. those containing an allylic hydrogen or allylic alcohol group, to the corresponding enones, using a ruthenium-based catalyst in the presence of a hydroperoxide. Particularly, &Dgr;-5-steroidal alkenes can be oxidized to the corresponding &Dgr;-5-7-keto alkenes.
    Type: Grant
    Filed: September 30, 1996
    Date of Patent: April 9, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Ross A. Miller, Andrew S. Thompson, Raman K. Bakshi, Edward G. Corley
  • Publication number: 20010039268
    Abstract: A subject of the invention is the compounds of formula (I): 1
    Type: Application
    Filed: December 8, 2000
    Publication date: November 8, 2001
    Applicant: Hoechst Marion Roussel
    Inventors: Yamina Bouali, Francois Nique, Jean-Georges Teutsch, Patrick Van De Velde
  • Patent number: 6288041
    Abstract: Sialic acid derivatives represented by the following general formula: wherein R1 represents a residue of a steroid compound excluding cholestane and cholestene residues, R2 represents hydrogen or methyl group, R3 represents a C1-C6 alkyl group and other, R4 represents hydrogen or acyl group, R5 represents a group of R15O— (R15 represents a C2-C7 acyl group and other), and X represents oxygen or sulfur atom, and their derivatives. These derivatives have activating effect on choline acetyltransferase activity in the chlonergic neurons, and are useful for preventive and therapeutic treatment of dementia, memory disorder, peripheral nervous disorder and so forth.
    Type: Grant
    Filed: December 19, 1997
    Date of Patent: September 11, 2001
    Assignee: Mitsubishi Chemical Corporation
    Inventors: Haruyuki Chaki, Naoko Ando, Tetsuo Jikihara, Ken-ichi Saito, Tomoko Yugami
  • Patent number: 6262042
    Abstract: The invention is directed to a novel class of steroids which exhibit potent antiprogestational activity.
    Type: Grant
    Filed: May 29, 1998
    Date of Patent: July 17, 2001
    Assignee: Research Triangle Institute
    Inventors: C. Edgar Cook, John A. Kepler, Gary S. Bartley
  • Patent number: 6143736
    Abstract: Methods, compositions, and compounds for modulating the GABA.sub.A receptor-chloride ionophore complex to alleviate stress, anxiety, seizures, mood disorders, PMS and PND and to induce anesthesia.
    Type: Grant
    Filed: July 8, 1999
    Date of Patent: November 7, 2000
    Assignee: CoCensys, Inc.
    Inventors: Ravindra B. Upasani, Haiji Xia, Derk Hogenkamp
  • Patent number: 5939545
    Abstract: Methods, compositions, and compounds for modulating the GABA.sub.A receptor-chloride ionophore complex to alleviate stress, anxiety, seizures, mood disorders, PMS and PND and to induce anesthesia.
    Type: Grant
    Filed: July 2, 1997
    Date of Patent: August 17, 1999
    Assignee: CoCensys, Inc.
    Inventors: Ravindra B. Upasani, Haiji Xia, Derk Hogenkamp
  • Patent number: 5902888
    Abstract: Disclosed are 6.alpha.-derivatized estriol compounds which, when conjugated to a protein, are useful in the in vivo preparation of antibodies specific to estriol. When labeled with a detectable label, the estriol derivatives are useful as haptens in a competitive immunoassay for estriol which demonstrate superior sensitivity with respect to estriol specific antibodies.
    Type: Grant
    Filed: November 14, 1997
    Date of Patent: May 11, 1999
    Assignee: Bayer Corporation
    Inventors: James V. Freeman, Gary M. Johnson
  • Patent number: 5861492
    Abstract: The invention relates to methods that permit the rapid construction of oligosaccharides and other glycoconjugates. Methods for forming multiple glycosidic linkages in solution in a single step are disclosed. The invention takes advantage of the discovery that the relative reactivity of glycoside residues containing anomeric sulfoxides and nucleophilic functional groups can be controlled. In another aspect of the invention, the reactivity of activated anomeric sugar sulfoxides is utilized in a solid phase method for the formation of glycosidic linkages. The methods disclosed may be applied to the preparation of specific oligosaccharides and other glycoconjugates, as well as to the preparation of glycosidic libraries comprising mixtures of various oligosaccharides, including glycoconjugates, which can be screened for biological activity.
    Type: Grant
    Filed: January 9, 1997
    Date of Patent: January 19, 1999
    Assignee: The Trustees of Princeton University
    Inventor: Daniel Evan Kahne
  • Patent number: 5856535
    Abstract: An aminosterol compound according to the following formula: ##STR1## wherein: R.sub.1 is a member selected from the group of: ##STR2## R.sub.2 is H or OH; R.sub.3 is H or OH;R.sub.4 is H or OH; andR.sub.5 is a C.sub.1 to C.sub.12 alkyl group.Preferably, R.sub.5 is a C.sub.1 to C.sub.6 alkyl group, and a methyl group is particularly preferred.
    Type: Grant
    Filed: December 18, 1996
    Date of Patent: January 5, 1999
    Assignee: Magainin Pharmaceuticals, Inc.
    Inventors: Michael Zasloff, William Kinney, Steven Jones
  • Patent number: 5843933
    Abstract: Compounds of formula I ##STR1## wherein X, R.sup.1, R.sup.2, R.sup.3 and R.sup.4 have the meanings indicated in the description, are described, as well as processes for their production, pharmaceutical preparations containing these compounds as well as their use for treatment of diseases. The compounds have antigestagenic, antiglucocorticoid, antimineralocorticoid and antiandrogenic properties.
    Type: Grant
    Filed: May 3, 1995
    Date of Patent: December 1, 1998
    Assignee: Schering Aktiengesellschaft
    Inventors: Arwed Cleve, Cornelius Scheidges, Gunter Neef, Eckhard Ottow, Walter Elger, Sybille Beier
  • Patent number: 5668126
    Abstract: Bile acid derivatives of the formula IW--X--Gin which G is a bile acid radical, W is an active compound moiety of a medicament and X is a bonding member between a bile acid radical and active compound moiety, are outstandingly suitable for introducing active compounds into the enterohepatic circulation. The compounds I are absorbed and pass into the bloodstream. It is possible in this way, using the natural reabsorption of the bile acids, to achieve improved absorption of non-absorbable or poorly absorbable pharmaceuticals.W may be, for example, a peptide, an antibiotic, an antiviral substance, an anticancer agent, a hepatoprotective agent, an antihyperlipidemic, a diuretic, a hypotensive, a renin inhibitor, a substance for the treatment of cirrhosis of the liver or a substance for the treatment of diabetes.G is a bile acid radical in the form of the free natural or chemically modified acids, the esters and amides, the salt forms and forms derivatized on alcohol groups.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: September 16, 1997
    Assignee: Hoechst Aktiengesellschaft
    Inventors: Werner Kramer, Gunther Wess
  • Patent number: 5646272
    Abstract: Bile acid derivatives of the formula IW--X--Gin which G is a bile acid radical, W is an active compound moiety of a medicament and X is a bonding member between a bile acid radical and active compound moiety, are outstandingly suitable for introducing active compounds into the entercepatic circulation. The compounds I are absorbed and pass into the bloodstream. It is possible in this way, using the natural reabsorption of the bile acids, to achieve improved absorption of non-absorbable or poorly absorbable pharmaceuticals.W may be, for example, a peptide, an antibiotic, an antiviral substance, an anticancer agent, a hepatoprotective agent, an antihyperlipidemic, a diuretic, a hypotensive, a renin inhibitor, a substance for the treatment of cirrhosis of the liver or a substance for the treatment of diabetes.G is a bile acid radical in the form of the free natural or chemically modified acids, the esters and amides, the salt forms and forms derivatized on alcohol groups.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: July 8, 1997
    Assignee: Hoechst Aktiengesellschaft
    Inventors: Werner Kramer, Gunther Wess
  • Patent number: 5646316
    Abstract: The present invention relates to a bile acid derivative, which comprises a bile acid derivatized at the carboxyl group with a hydroxamic acid or hydroxamate ester. The carboxyl group in the bile acid compound can also be derivatized with an amino acid or oligopeptide, whose C-terminus is derivatized with a hydroxamic acid or a hydroxamate ester. The present invention also relates to a method of use of a bile acid or a bile acid derivative to inhibit a metalloproteinase enzyme, comprising contacting a metalloproteinase with an effective amount of a bile acid or bile acid derivative. In another embodiment, the present invention further relates to a method of use of a bile acid or bile acid derivative to therapeutically treat a disease, which is ameliorated by inhibiting a metalloproteinase enzyme. In this method, a therapeutically effective amount of a bile acid, a bile acid derivative or physiologically acceptable salts thereof, is administered to a human or other mammal.
    Type: Grant
    Filed: April 25, 1995
    Date of Patent: July 8, 1997
    Assignee: OsteoArthritis Sciences, Inc.
    Inventors: Alan R. Jacobson, Douglas G. Gabler, Jozef Oleksyszyn
  • Patent number: 5637691
    Abstract: Compounds having a broad range of antimicrobial activity generally have a structure including asteroid nucleus with a cationic, preferably polyamine, side chain (X) and an anionic side chain (Y). The invention is also directed to compounds of the Formula III: ##STR1## preferably where the steroid ring nucleus is saturated; the steroid ring substituent Z.sub.5 is .alpha.-H; one Z.sub.7 is .beta.-H and the other is .alpha.-H or .alpha.-OH; both substituents Z.sub.12 are hydrogen; X' is a polyamine side chain of the formula --NH--(CH.sub.2).sub.p --NH--(CH.sub.2).sub.q --N(R.sup.II)(R.sup.III) where p and q are each independently 3 or 4, and R.sup.II and R.sup.III are each independently hydrogen or methyl; R' is methyl; and Y' is (C.sub.1 -C.sub.10)-alkyl substituted with a group such as --CO.sub.2 H or --SO.sub.3 H.
    Type: Grant
    Filed: August 18, 1994
    Date of Patent: June 10, 1997
    Assignee: Magainin Pharmaceuticals, Inc.
    Inventors: Leah L. Frye, Michael A. Zasloff, William A. Kinney, Robert Moriarty
  • Patent number: 5620966
    Abstract: The invention relates to a 11,21-bisphenyl-19-norpregnane derivative of formula I ##STR1## wherein R.sub.1 is selected from H, halogen, (1-6C)alkoxy, and NR.sub.5 R.sub.6, R.sub.5 and R.sub.6 being independently hydrogen or (1-6C)alkyl or R.sub.5 and R.sub.6 together are (3-6C)alkylene; R.sub.2 is hydrogen; or R.sub.1 and R.sub.2 together are a (1-3C)alkylenedioxy group, optionally substituted by one or more halogen atoms; R.sub.3 is methyl or ethyl; R.sub.4 is selected from C(O)-NR.sub.5 R.sub.6, SO.sub.n -(1-6C)alkyl optionally substituted by one or more halogen atoms, SO.sub.n -(3-6C)cycloalkyl, n being 1 or 2, SO.sub.2 -NR.sub.5 R.sub.6, 2-oxypyrrolidinyl, and NR.sub.5 R.sub.6 ; R.sub.7 is H or (1-6C)alkyl; R.sub.8 is H or carboxy-1-oxo(1-6C)alkyl; and X is selected from (H,OH), O, and NOH; 11 or a pharmaceutically acceptable salt thereof.The compounds of the invention have anti-glucocorticoid activity and can be used in treating or preventing glucocorticoid-dependent diseases.
    Type: Grant
    Filed: May 19, 1995
    Date of Patent: April 15, 1997
    Assignee: Akzo Nobel N.V.
    Inventors: Ronald Gebhard, Hendrikus A. A. van der Voort
  • Patent number: 5599806
    Abstract: The invention describes hydrazino and hydroxyamino-14.beta.-hydroxyandrostane derivatives having general formula (I): ##STR1## wherein the symbol means .alpha. or .beta. configuration and A, B, R.sup.1, R.sup.2, R.sup.3, and R.sup.4 have the meanings given in the description and their use in the treatment of cardiovascular disorders such as heart failure and hypertension.
    Type: Grant
    Filed: May 18, 1995
    Date of Patent: February 4, 1997
    Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
    Inventors: Alberto Cerri, Giuseppe Bianchi, Patrizia Ferrari, Elena Folpini, Piero Melloni
  • Patent number: 5591733
    Abstract: Method, compositions, and compounds for modulating brain excitability to alleviate stress, anxiety, insomnia and seizure activity using certain steroid derivatives that act at a newly identified site on the gamma-aminobutyric acid receptor-chloride ionophore (GR) complex.
    Type: Grant
    Filed: August 2, 1993
    Date of Patent: January 7, 1997
    Assignee: University of Southern California
    Inventors: Michael B. Bolger, Kelvin W. Gee, Nancy C. Lan, Robert H. Purdy, Seid Mirsadeghi, Syed Hasan Tahir, Delia Belelli
  • Patent number: 5571795
    Abstract: Novel glycosylated steroid derivatives for facilitating the transport of compounds across biological membranes, either in admixture or as conjugates, are disclosed. A novel process for efficient synthesis of these glycosylated steroid derivatives, using activated glycosyl sulfoxide intermediates is also provided.
    Type: Grant
    Filed: December 14, 1992
    Date of Patent: November 5, 1996
    Assignee: The Trustees of Princeton University
    Inventors: Daniel E. Kahne, Suzanne Walker Kahne
  • Patent number: 5547949
    Abstract: Novel, therapeutically active 21-aminosteroids of formula (I) ##STR1## with pregnane skeleton, are disclosed wherein two of X, Y and Z are a nitrogen atom each and the third one is a methine group; R.sup.1 and R.sup.2 are independently from each other, a primary amino group bearing as substituent a branched-chain C.sub.4-8 alkyl -alkenyl or -alkynyl group, or a C.sub.4-10 cycloalkyl group comprising 1 to 3 ring(s) and being optionally substituted by at least one C.sub.1-3 alkyl group; or R.sup.1 and R.sup.2 are each a spiro-heterocyclic secondary amino group containing at most 10 carbon atoms and optionally at least one oxygen atom as additional heteroatom; or one of R.sup.1 and R.sup.2 is an unsubstituted heterocyclic secondary amino group containing 4 to 7 carbon atoms and the other one is an above-identified primary amino group, an above-identified spiro-heterocyclic secondary amino group, or a heterocyclic secondary amino group containing 4 to 7 carbon atoms and substituted by at least one C.sub.
    Type: Grant
    Filed: December 8, 1994
    Date of Patent: August 20, 1996
    Assignee: Richter Gedeon Vegyeszeti Gyar Rt.
    Inventors: Sandor Maho, Zoltan Tuba, Aniko Gere, Pal Vittay, Bela Kiss, Eva Palosi, Laszlo Szporny, Erzsebet C. Francsicsne, Anna M. Boorne, Gabor Balogh, Sandor Gorog
  • Patent number: 5462933
    Abstract: Bile acid derivatives, processes for their preparation and use as pharmaceuticals Bile acid derivatives of the formula IW--X--Gin which G is a bile acid radical, W is an active compound moiety of a medicament and X is a bonding member between a bile acid radical and active compound moiety, are outstandingly suitable for introducing active compounds into the enterohepatic circulation. The compounds I are absorbed and pass into the bloodstream. It is possible in this way, using the natural reabsorption of the bile acids, to achieve improved absorption of non-absorbable or poorly absorbable pharmaceuticals.W may be, for example, a peptide, an antibiotic, an antiviral substance, an anticancer agent, a hepatoprotective agent, an antihyperlipidemic, a diuretic, a hypotensive, a renin inhibitor, a substance for the treatment of cirrhosis of the liver or a substance for the treatment of diabetes.
    Type: Grant
    Filed: March 10, 1994
    Date of Patent: October 31, 1995
    Assignee: Hoechst Aktiengesellschaft
    Inventors: Werner Kramer, Gunther Wess
  • Patent number: RE35053
    Abstract: Disclosed are .DELTA..sup.9(11) -steroids (VI) and amino substituted steroids (XI) which contain an amino group attached to the terminal carbon atom of the C.sub.17 -side chain, more particularly amino steroids (Ia and Ib), aromatic steroids (II), .DELTA..sup.16 -steroids (IIIa and IIIb), reduced A-ring steroids (IV), .DELTA..sup.17(20) -steroids (Va and Vb) and .DELTA..sup.9(11) -steroids (VI) which are useful as pharmaceutical agents for treating a number of conditions.
    Type: Grant
    Filed: October 9, 1992
    Date of Patent: October 10, 1995
    Assignee: The Upjohn Company
    Inventors: John M. McCall, E. Jon Jacobsen
  • Patent number: RE35517
    Abstract: Method, compositions, and compounds for modulating brain excitability to alleviate stress, anxiety, and seizure activity using certain steroid derivatives that act at a newly identified site on the gamma-ammobutyric acid/benzodiazepine receptor-chloride ionpore (GBR) complex.
    Type: Grant
    Filed: November 23, 1992
    Date of Patent: May 20, 1997
    Assignee: University of Southern California
    Inventors: Kelvin W. Gee, Michael B. Bolger, Nancy C. Lan